Recombinant human adenovirus type 5
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Recombinant human adenovirus type 5, covering 2016-10-21 to 2026-01-21. Get the full timeline:
Most recent: Clinical Trial Update: Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety [Phase 2]